Peripheral vs. Central sex steroid hormones in experimental parkinson's disease

Frontiers in Endocrinology

Volumn 2, Issue NOV, 2011, Pages

  McArthur, Simon ^a   Gillies, Glenda E ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Central vs. gonadal steroids; Estrogen; Nigrostriatal pathway; Parkinson's disease; Sex

Indexed keywords

EID: 84874372095     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2011.00082     Document Type: Review

References (184)

1. Alves, G., Muller, B., Herlofson, K., Hogenesch, I., Telstad, W., Aarsland, D., Tysnes, O. B., and Larsen, J. P. (2009). Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study. J. Neurol. Neurosurg. Psychiatr. 80, 851-857.
2. Arevalo, M. A., Diz-Chaves, Y., Santos-Galindo, M., Bellini, M. J., and Garcia-Segura, L. M. (2011). Selective oestrogen receptor modulators decrease the inflammatory response of glial cells. J. Neu-roendocrinol. doi: 10.1111/j.1365-2826.2011.02156.x. [Epub ahead of print].
3. Auluck, P. K., Caraveo, G., and Lindquist, S. (2010). alpha-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annu. Rev. Cell Dev. Biol. 26, 211-233.
4. Azcoitia, I., Santos-Galindo, M., Arevalo, M. A., and Garcia-Segura, L. M. (2010). Role of astroglia in the neuroplastic and neuroprotective actions of estradiol. Eur. J. Neurosci. 32, 1995-2002.
5. Azcoitia, I., Sierra, A., and Garcia-Segura, L. M. (1999). Localization of estrogen receptor beta-immunoreactivity in astrocytes of the adult rat brain. Glia 26, 260-267.
6. Azcoitia, I., Sierra, A., Veiga, S., and Garcia-Segura, L. M. (2003). Aromatase expression by reactive astroglia is neuroprotective. Ann. N. Y. Acad. Sci. 1007, 298-305.
7. Azcoitia, I., Sierra, A., Veiga, S., and Garcia-Segura, L. M. (2005). Brain steroidogenesis: emerging therapeutic strategies to prevent neurode-generation. J. Neural Transm. 112, 171-176.
8. Azcoitia, I., Sierra, A., Veiga, S., Honda, S., Harada, N., and Garcia-Segura, L. M. (2001). Brain aromatase is neuroprotective. J. Neurobiol. 47, 318-329.
9. Azcoitia, I., Yague, J. G., and Garcia-Segura, L. M. (2011). Estradiol synthesis within the human brain. Neu-roscience 191, 139-147.
10. Azevedo, R. B., Lacava, Z. G., Miyasaka, C. K., Chaves, S. B., and Curi, R. (2001). Regulation of antioxidant enzyme activities in male and female rat macrophages by sex steroids. Braz. J. Med. Biol. Res. 34, 683-687.
11. Baba, Y., Putzke, J. D., Whaley, N. R., Wszolek, Z. K., and Uitti, R. J. (2005). Gender and the Parkinson's disease phenotype. J. Neurol. 252, 1201-1205.
12. Baker, A. E., Brautigam, V. M., and Wat-ters, J. J. (2004). Estrogen modulates microglial inflammatory mediator production via interactions with estrogen receptor beta. Endocrinology 145, 5021-5032.
13. Baldereschi, M., Di Carlo, A., Rocca, W. A., Vanni, P., Maggi, S., Perissinotto, E., Grigoletto, F., Amaducci, L., and Inzitari, D. (2000). Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 55, 1358-1363.
14. Balthazart, J., Baillien, M., and Ball, G. F. (2002). Interactions between aromatase (estrogen synthase) and dopamine in the control of male sexual behavior in quail. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 132, 37-55.
15. Balthazart, J., and Ball, G. F. (2006). Is brain estradiol a hormone or a neu-rotransmitter? Trends Neurosci. 29, 241-249.
16. Banati, R. B., Daniel, S. E., and Blunt, S. B. (1998). Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov. Disord. 13, 221-227.
17. Barres, B. A. (2008). The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 60, 430-440.
18. Bassilana, F., Mace, N., Li, Q., Stutz-mann, J. M., Gross, C. E., Pradier, L., Benavides, J., Menager, J., and Bezard, E. (2005). Unraveling sub-stantia nigra sequential gene expression in a progressive MPTP-lesioned macaque model of Parkinson's disease. Neurobiol. Dis. 20, 93-103.
19. Becker, J. B. (1999). Gender differences in dopaminergic function in stria-tum and nucleus accumbens. Pharmacol. Biochem. Behav. 64, 803-812.
20. Behl, C. (2002). Oestrogen as a neuro-protective hormone. Nat. Rev. Neu-rosci. 3, 433-442.
21. Benedetti, M. D., Maraganore, D. M., Bower, J. H., Mcdonnell, S. K., Peterson, B. J., Ahlskog, J. E., Schaid, D. J., and Rocca, W. A. (2001). Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov. Disord. 16, 830-837.
22. Bezard, E., Dovero, S., Prunier, C., Ravenscroft, P., Chalon, S., Guil-loteau, D., Crossman, A. R., Bioulac, B., Brotchie, J. M., and Gross, C. E. (2001). Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 21, 6853-6861.
23. Bezard, E., Gross, C. E., and Brotchie, J. M. (2003). Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci. 26, 215-221.
24. Bixo, M., Andersson, A., Winblad, B., Purdy, R. H., and Backstrom, T. (1997). Progesterone, 5alpha-pregnane-3,20-dione and 3alpha-hydroxy-5alpha-pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res. 764, 173-178.
25. Block, M. L., Zecca, L., and Hong, J. S. (2007). Microglia-mediated neuro-toxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8, 57-69.
26. Blum, D., Torch, S., Lambeng, N., Nis-sou, M.-F., Benabid, A.-L., Sadoul, R., and Verna, J.-M. (2001). Molecular pathways involved in the neuro-toxicity of 6-OHDA, dopamine and MPTP: contribution to the apop-totic theory in Parkinson's disease. Prog. Neurobiol. 65, 135-172.
27. Blurton-Jones, M., and Tuszynski,M. H. (2001). Reactive astrocytes express estrogen receptors in the injured primate brain. J. Comp. Neurol. 433, 115-123.
28. Boon, W. C., Chow, J. D., and Simpson, E. R. (2010). The multiple roles of estrogens and the enzyme aromatase. Prog. Brain Res. 181, 209-232.
29. Bourque, M., Dluzen, D. E., and Di Paolo, T. (2009). Neuroprotective actions of sex steroids in Parkinson's disease. Front. Neuroendocrinol. 30, 142-157.
30. Braak, H., Del Tredici, K., Rub, U., De Vos, R. A., Jansen Steur, E. N., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211.
31. Brann, D. W., Dhandapani, K., Wakade, C., Mahesh, V. B., and Khan, M. M. (2007). Neurotrophic and neuro-protective actions of estrogen: basic mechanisms and clinical implications. Steroids 72, 381-405.
32. Cantuti-Castelvetri, I., Keller-Mcgandy, C., Bouzou, B., Asteris, G., Clark, T. W., Frosch, M. P., and Standaert, D. G. (2007). Effects of gender on nigral gene expression and Parkinson disease. Neurobiol. Dis. 26, 606-614.
33. Carswell, H. V., Dominiczak, A. F., Garcia-Segura, L. M., Harada, N., Hutchison, J. B., and Macrae, I. M. (2005). Brain aromatase expression after experimental stroke: topography and time course. J. Steroid Biochem. Mol. Biol. 96, 89-91.
34. Castaneda, E., Whishaw, I. Q., and Robinson, T. E. (1990). Changes in striatal dopamine neurotrans-mission assessed with microdialy-sis following recovery from a bilateral 6-OHDA lesion: variation as a function of lesion size. J. Neurosci. 10, 1847-1854.
35. Cerciat, M., Unkila, M., Garcia-Segura, L. M., and Arevalo, M. A. (2010). Selective estrogen receptor modulators decrease the production of interleukin-6 and interferon-gamma-inducible protein-10 by astrocytes exposed to inflammatory challenge in vitro. Glia 58, 93-102.
36. Chung, S. J., Armasu, S. M., Biernacka, J. M., Lesnick, T. G., Rider, D. N., Cunningham, J. M., and Maraganore, D. M. (2011). Variants in estrogen-related genes and risk of Parkinson's disease. Mov. Disord. 26, 1234-1242.
37. Cordellini, M. F., Piazzetta, G., Pinto, K. C., Delattre, A. M., Matheussi, F., Carolino, R. O., Szawka, R. E., Anselmo-Franci, J. A., and Ferraz, A. C. (2011). Effect of different doses of estrogen on the nigros-triatal dopaminergic system in two 6-hydroxydopamine-induced lesion models of Parkinson's disease. Neu-rochem. Res. 36, 955-961.
38. Cosimo Melcangi, R., and Garcia-Segura, L. M. (2010). Sex-specific therapeutic strategies based on neu-roactive steroids: in search for innovative tools for neuroprotection. Horm. Behav. 57, 2-11.
39. Craig, M. C., and Murphy,D. G. (2007). Estrogen: effects on normal brain function and neuropsychiatric disorders. Climacteric 10(Suppl. 2), 97-104.
40. Currie, L. J., Harrison, M. B., Trugman, J. M., Bennett, J. P., and Wooten, G. F. (2004). Postmenopausal estrogen use affects risk for Parkinson disease. Arch. Neurol. 61, 886-888.
41. Das, K., Ghosh, M., Nag, C., Nandy, S. P., Banerjee, M., Datta, M., Devi, G., and Chaterjee, G. (2011). Role of familial, environmental and occupational factors in the development of Parkinson's disease. Neurodegener. Dis. 8, 345-351.
42. Datla, K. P., Murray, H. E., Pillai, A. V., Gillies, G. E., and Dexter, D. T. (2003). Differences in dopaminergic neuroprotective effects of estrogen during estrous cycle. Neuroreport 14, 47-50.
43. DeGiorgio, L. A., Attardi, B., Shimizu,Y., Ogata, M., and Volpe, B. T. (2002). 17 beta-estradiol treatment retards excitotoxic delayed degeneration in substantia nigra reticulata neurons. Brain Res. 936, 15-20.
44. Dewing, P., Chiang, C. W., Sinchak, K., Sim, H., Fernagut, P. O., Kelly, S., Chesselet, M. F., Micevych, P. E., Albrecht, K. H., Harley, V. R., and Vilain, E. (2006). Direct regulation of adult brain function by the male-specific factor SRY. Curr. Biol. 16, 415-420.
45. di Michele, F., Longone, P., Romeo, E., Lucchetti, S., Brusa, L., Pieran-tozzi, M., Bassi, A., Bernardi, G., and Stanzione, P. (2003). Decreased plasma and cerebrospinal fluid content of neuroactive steroids in Parkinson's disease. Neurol. Sci. 24, 172-173.
46. Dluzen, D. (1997). Estrogen decreases corpus striatal neurotoxicity in response to 6- hydroxydopamine. Brain Res. 767, 340-344.
47. Dluzen, D., and Horstink, M. (2003). Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies. Endocrine 21, 67-75.
48. Dluzen, D., Jain, R., and Liu, B. (1994). Modulatory effects of testosterone on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurochem. 62, 94-101.
49. Dluzen, D. E. (1996). Effects of testosterone upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system of C57/B1 mice. Brain Res. 715, 113-118.
50. Dluzen, D. E. (2000). Neuroprotective effects of estrogen upon the nigros-triatal dopaminergic system. J. Neu-rocytol. 29, 387-399.
51. Dluzen, D. E. (2005). Unconventional effects of estrogen uncovered. Trends Pharmacol. Sci. 26, 485-487.
52. Dluzen, D. E., Anderson, L. I., and Pilati, C.F. (2002). Methamphetamine-gonadal steroid hormonal interac tions: effects upon acute toxicity and striatal dopamine concentrations. Neurotoxicol. Teratol. 24, 267-273.
53. Dluzen, D. E., and Liu, B. (2008). Gender differences in methamphet-amine use and responses: a review. Gend. Med. 5, 24-35.
54. Do Rego, J. L., Seong, J. Y., Burel, D., Leprince, J., Luu-the, V., Tsut-sui, K., Tonon, M. C., Pelletier, G., and Vaudry, H. (2009). Neuros-teroid biosynthesis: enzymatic pathways and neuroendocrine regulation by neurotransmitters and neu-ropeptides. Front. Neuroendocrinol. 30, 259-301.
55. Ekue, A., Boulanger, J. F., Morissette, M., and Di Paolo, T. (2002). Lack of effect of testosterone and dihydrotestosterone compared to 17beta-oestradiol in 1-methyl-4-phenyl-1,2,3,6, tetrahydropy-ridine-mice. J. Neuroendocrinol. 14, 731-736.
56. Elbaz, A., Bower, J. H., Maraganore, D M., Mcdonnell, S. K., Peterson, B. J., Ahlskog, J. E., Schaid, D. J., and Rocca, W. A. (2002). Risk tables for parkinsonism and Parkinson's disease. J. Clin. Epidemiol. 55, 25-31.
57. Farina, C., Aloisi, F., and Meinl, E. (2007). Astrocytes are active players in cerebral innate immunity. Trends Immunol. 28, 138-145.
58. Federman, D. D. (2006). The biology of human sex differences. N. Engl. J. Med. 354, 1507-1514.
59. Ferraz, A. C., Matheussi, F., Szawka, R. E., Rizelio, V., Delattre, A. M., Rigon, P., Hermel Edo, E., Xavier, L. L.,Achaval, M., and Anselmo-Franci, J. A. (2008). Evaluation of estrogen neuroprotective effect on nigrostri-atal dopaminergic neurons following 6-hydroxydopamine injection into the substantia nigra pars com-pacta or the medial forebrain bundle. Neurochem. Res. 33, 1238-1246.
60. Ferraz, A. C., Xavier, L. L., Hernan-des, S., Sulzbach, M., Viola, G. G., Anselmo-Franci, J. A., Achaval, M., and Da Cunha, C. (2003). Failure of estrogen to protect the substan-tia nigra pars compacta of female rats from lesion induced by 6-hydroxydopamine. Brain Res. 986, 200-205.
61. Fink, G., Sumner, B. E., Rosie, R., Grace, O., and Quinn, J. P. (1996). Estrogen control of central neurotransmis-sion: effect on mood, mental state, and memory. Cell. Mol. Neurobiol. 16, 325-344.
62. Fox, S. H., and Brotchie, J. M. (2010). The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future. Prog. Brain Res. 184, 133-157.
63. Gao, X., and Dluzen, D. E. (2001). The effect of testosterone upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Brain Res. 892, 63-69.
64. Garcia-Ovejero, D., Azcoitia, I., Don-carlos, L. L., Melcangi, R. C., and Garcia-Segura, L. M. (2005). Glia-neuron crosstalk in the neuroprotec-tive mechanisms of sex steroid hormones. Brain Res. Brain Res. Rev. 48, 273-286.
65. Garcia-Segura, L. M. (2008). Aromatase in the brain: not just for reproduction anymore. J. Neuroendocrinol. 20, 705-712.
66. Garcia-Segura, L. M., Azcoitia, I., and Doncarlos, L. L. (2001). Neuropro-tection by estradiol. Prog. Neurobiol. 63, 29-60.
67. Garcia-Segura, L. M., Wozniak, A., Azcoitia, I., Rodriguez, J. R., Hutchison, R. E., and Hutchison, J. B. (1999). Aromatase expression by astrocytes after brain injury: implications for local estrogen formation in brain repair. Neuroscience 89, 567-578.
68. Gillies, G. E., and McArthur, S. (2010a). Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines. Pharmacol. Rev. 62, 155-198.
69. Gillies, G. E., and McArthur, S. (2010b). Independent influences of sex steroids of systemic and central origin in a rat model of Parkinson's disease: a contribution to sex-specific neuroprotection by estrogens. Horm. Behav. 57, 23-34.
70. Gillies, G. E., Murray, H. E., Dexter, D., and Mcarthur,S. (2004). Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease. Pharmacol. Biochem. Behav. 78, 513-522.
71. Glinka, Y., Tipton, K. F., and Youdim, M. B. (1996). Nature of inhibition of mitochondrial respiratory complex I by 6-Hydroxydopamine. J. Neurochem. 66, 2004-2010.
72. Gottfried-Blackmore, A., Sierra, A., Jellinck, P. H., Mcewen, B. S., and Bulloch, K. (2008). Brain microglia express steroid-converting enzymes in the mouse. J. Steroid Biochem. Mol. Biol. 109, 96-107.
73. Green, P. S., and Simpkins, J. W. (2000). Neuroprotective effects of estrogens: potential mechanisms of action. Int. J. Dev. Neurosci. 18, 347-358.
74. Haaxma, C. A., Bloem, B. R., Borm, G. F., Oyen, W. J., Leenders, K. L., Eshuis, S., Booij, J., Dluzen, D. E., and Horstink, M. W. (2007). Gender differences in Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 78, 819-824.
75. Hakansson, A., Westberg, L., Nilsson, S., Buervenich, S., Carmine, A., Holmberg, B., Sydow, O., Olson, L., Johnels, B., Eriksson, E., and Nissbrandt, H. (2005). Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor beta on the susceptibility to Parkinson's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 133B, 88-92.
76. Halassa, M. M., and Haydon, P. G. (2010). Integrated brain circuits: astrocytic networks modulate neu-ronal activity and behavior. Annu. Rev. Physiol. 72, 335-355.
77. Halliday, G. M., and Stevens, C. H. (2011). Glia: initiators and progres-sors of pathology in Parkinson's disease. Mov. Disord. 26, 6-17.
78. Hamby, M. E., and Sofroniew, M. V. (2010). Reactive astrocytes as therapeutic targets for CNS disorders. Neurotherapeutics 7, 494-506.
79. Hamza, T. H., Zabetian, C. P., Tenesa, A., Laederach, A., Montimurro, J., Yearout, D., Kay, D. M., Doheny, K. F., Paschall, J., Pugh, E., Kusel, V. I., Collura, R., Roberts, J., Griffith, A., Samii, A., Scott, W. K., Nutt, J., Factor, S. A., and Payami, H. (2010). Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat. Genet. 42, 781-785.
80. Hirsch, E. C., Hunot, S., Damier, P., and Faucheux, B. (1998). Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann. Neurol. 44, S115-S120.
81. Hu, M., Crombag, H. S., Robinson, T. E., and Becker, J. B. (2004). Biological basis of sex differences in the propensity to self-administer cocaine. Neuropsychopharmacology 29, 81-85.
82. Hu, M., Watson, C. J., Kennedy, R. T., and Becker, J. B. (2006). Estradiol attenuates the K+-induced increase in extracellular GABA in rat stria-tum. Synapse 59, 122-124.
83. Hunot, S., Boissiere, F., Faucheux, B., Brugg, B., Mouatt-Prigent, A., Agid, Y., and Hirsch, E. C. (1996). Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuro-science 72, 355-363.
84. Hurn, P. D., and Macrae, I. M. (2000). Estrogen as a neuroprotectant in stroke. J. Cereb. Blood Flow Metab. 20, 631-652.
85. Jones, M. E., Chin Boon, W., Proietto, J., and Simpson, E. R. (2006). Of mice and men: the evolving pheno-type of aromatase deficiency. Trends Endocrinol. Metab. 17, 55-64.
86. Kaminsky, Z., Wang, S. C., and Petro-nis,A. (2006). Complex disease, gender and epigenetics. Ann. Med. 38, 530-544.
87. Kipp, M., Karakaya, S., Johann, S., Kampmann, E., Mey, J., and Beyer, C. (2007). Oestrogen and progesterone reduce lipopolysaccharide-induced expression of tumour necrosis factor-alpha and interleukin-18 in midbrain astrocytes. J. Neuroen-docrinol. 19, 819-822.
88. Kipp, M., Karakaya, S., Pawlak, J., Araujo-Wright, G., Arnold, S., and Beyer, C. (2006). Estrogen and the development and protection of nigrostriatal dopaminergic neurons: concerted action of a multitude of signals, protective molecules, and growth factors. Front. Neuroen-docrinol. 27, 376-390.
89. Klegeris, A., Mcgeer, E. G., and Mcgeer, P. L. (2007). Therapeutic approaches to inflammation in neurodegenera-tive disease. Curr. Opin. Neurol. 20, 351-357.
90. Klein, C., and Schlossmacher, M. G. (2007). Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology 69, 2093-2104.
91. Klink, R., Robichaud, M., and Debon-nel, G. (2002). Gender and gonadal status modulation of dorsal raphe nucleus serotonergic neurons. Part II. Regulatory mechanisms. Neu-ropharmacology 43, 1129-1138.
92. Knott, C., Stern, G., and Wilkin, G. P. (2000). Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol. Cell. Neurosci. 16, 724-739.
93. Kritzer, M. F., and Creutz, L. M. (2008). Region and sex differences in constituent dopamine neurons and immunoreactivity for intracellular estrogen and androgen receptors in mesocortical projections in rats. J. Neurosci. 28, 9525-9535.
94. Kuppers, E., and Beyer, C. (1998). Expression of aromatase in the embryonic and postnatal mouse striatum. Brain Res. Mol. Brain Res. 63, 184-188.
95. Kuppers, E., Ivanova, T., Karolczak, M., and Beyer, C. (2000). Estrogen: a multifunctional messenger to nigrostriatal dopaminergic neurons. J. Neurocytol. 29, 375-385.
96. Lane, E.,and Dunnett,S. (2008). Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic? Psychopharma-cology (Berl.) 199, 303-312.
97. Lewis, C., and Dluzen, D. E. (2008). Testosterone enhances dopamine depletion by methamphetamine in male, but not female, mice. Neurosci. Lett. 448, 130-133.
98. Liu, B., and Dluzen, D. E. (2007). Oestrogen and nigrostriatal dopaminergic neurodegenera-tion: animal models and clinical reports of Parkinson's disease. Clin. Exp. Pharmacol. Physiol. 34, 555-565.
99. Liu, X., Fan, X. L., Zhao, Y., Luo, G. R., Li, X. P., Li, R., and Le, W. D. (2005). Estrogen provides neuroprotection against activated microglia-induced dopamin-ergic neuronal injury through both estrogen receptor-alpha and estrogen receptor-beta in microglia. J. Neurosci. Res. 81, 653-665.
100. Lucas, S. M., Rothwell, N. J., and Gibson, R. M. (2006). The role of inflammation in CNS injury and disease. Br. J. Pharmacol. 147(Suppl. 1), S232- S240.
101. Luchetti, S., Bossers, K., Frajese, G. V., and Swaab, D. F. (2010). Neuros-teroid biosynthetic pathway changes in substantia nigra and caudate nucleus in Parkinson's disease. Brain Pathol. 20, 945-951.
102. Marchetti, B., Serra, P. A., L'episcopo, F., Tirolo, C., Caniglia, S., Testa, N., Cioni, S., Gennuso, F., Rocchitta, G., Desole, M. S., Mazzarino, M. C., Miele, E., and Morale, M. C. (2005). Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: glia as a common final pathway. Ann. N. Y. Acad. Sci. 1057, 296-318.
103. Marien, M. R., Colpaert, F. C., and Rosenquist, A. C. (2004). Noradren-ergic mechanisms in neurodegener-ative diseases: a theory. Brain Res. Brain Res. Rev. 45, 38-78.
104. Mattson, M. P. (2006). Neuronal life-and-death signaling, apopto-sis, and neurodegenerative disorders. Antioxid. Redox Signal. 8, 1997-2006.
105. McArthur, S., Cristante, E., Paterno, M., Christian, H., Roncaroli, F., Gillies, G. E., and Solito, E. (2010). Annexin A1: a central player in the anti-inflammatory and neuroprotective role of microglia. J. Immunol. 185, 6317-6328.
106. McArthur, S., Murray, H. E., Dhankot, A., Dexter, D. T., and Gillies, G. E. (2007). Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormone effects on cell survival and DAT expression but is exacerbated by central aromatase inhibition. J. Neurochem. 100, 678-692.
107. McDermott, J. L., Liu, B., and Dluzen, D. E. (1994). Sex differences and effects of estrogen on dopamine and DOPAC release from the striatum of male and female CD-1 mice. Exp. Neurol. 125, 306-311.
108. McEwen, B. S., and Alves, S. E. (1999). Estrogen actions in the central nervous system. Endocr. Rev. 20, 279-307.
109. McGeer, P. L., Itagaki, S., Boyes, B. E., and Mcgeer, E. G. (1988). Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38, 1285-1291.
110. Meissner, W. G., Frasier, M., Gasser, T., Goetz, C. G., Lozano, A., Piccini, P., Obeso, J. A., Rascol, O., Schapira, A., Voon, V., Weiner, D. M., Tison, F., and Bezard, E. (2011). Priorities in Parkinson's disease research. Nat. Rev. Drug Discov. 10, 377-393.
111. Melcangi, R. C., Caruso, D., Levan-dis, G., Abbiati, F., Armentero, M. T., and Blandini, F. (2010). Modifications of neuroactive steroid levels in an experimental model of nigrostriatal degeneration: potential relevance to the pathophysiol-ogy of Parkinson's disease. J. Mol. Neurosci. doi: 10.1007/s12031-011-9570-y. [Epub ahead of print].
112. Mensah-Nyagan, A. G., Do-Rego, J. L., Beaujean, D., Luu-the, V., Pelletier, G., and Vaudry, H. (1999). Neu-rosteroids: expression of steroido-genic enzymes and regulation of steroid biosynthesis in the central nervous system. Pharmacol. Rev. 51, 63-81.
113. Micevych, P., and Dominguez, R. (2009). Membrane estradiol signaling in the brain. Front. Neuroen-docrinol. 30, 315-327.
114. Miller, D. B., Ali, S. F., O'callaghan, J. P., and Laws, S. C. (1998). The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann. N. Y. Acad. Sci. 844, 153-165.
115. Miller, I. N., and Cronin-Golomb, A. (2010). Gender differences in Parkinson's disease: clinical characteristics and cognition. Mov. Disord. 25, 2695-2703.
116. Milner, T. A., Ayoola, K., Drake, C. T., Herrick, S. P., Tabori, N. E., Mcewen, B. S., Warrier, S., and Alves, S. E. (2005). Ultrastructural localization of estrogen receptor beta immunoreactivity in the rat hip-pocampal formation. J. Comp. Neu-rol. 491, 81-95.
117. Milner, T. A., Mcewen, B. S., Hayashi, S., Li, C. J., Reagan, L. P., and Alves, S. E. (2001). Ultrastructural evidence that hippocampal alpha estrogen receptors are located at extranu-clear sites. J. Comp. Neurol. 429, 355-371.
118. Minghetti,L. (2005). Role of inflammation in neurodegenerative diseases. Curr. Opin. Neurol. 18, 315-321.
119. Morale, M. C., L'episcopo, F., Tirolo, C., Giaquinta, G., Caniglia, S., Testa, N., Arcieri, P., Serra, P. A., Lupo, G., Alberghina, M., Harada, N., Honda, S., Panzica, G. C., and Marche-tti, B. (2008). Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease? Brain Res. Rev. 57, 431-443.
120. Morale, M. C., Serra, P. A., L'episcopo, F., Tirolo, C., Caniglia, S., Testa, N., Gennuso, F., Giaquinta, G., Roc-chitta, G., Desole, M. S., Miele, E., and Marchetti, B. (2006). Estrogen, neuroinflammation and neuropro-tection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration. Neuro-science 138, 869-878.
121. Morissette, M., and Di Paolo, T. (2009). Effect of estradiol on striatal dopamine activity of female hemi-parkinsonian monkeys. J. Neurosci. Res. 87, 1634-1644.
122. Moroz, I. A., Rajabi, H., Rodaros, D., and Stewart, J. (2003). Effects of sex and hormonal status on astrocytic basic fibroblast growth factor-2 and tyrosine hydroxylase immunoreactivity after medial fore-brain bundle 6-hydroxydopamine lesions of the midbrain dopamine neurons. Neuroscience 118, 463-476.
123. Mukai, H., Takata, N., Ishii, H. T., Tanabe, N., Hojo, Y., Furukawa, A., Kimoto, T., and Kawato, S. (2006). Hippocampal synthesis of estrogens and androgens which are paracrine modulators of synaptic plasticity: synaptocrinology. Neuroscience 138, 757-764.
124. Murray, H. E., Pillai, A. V., Mcarthur, S. R., Razvi, N., Datla, K. P., Dexter, D. T., and Gillies, G. E. (2003). Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminer-gic pathway of adult rats: differential actions of estrogen in males and females. Neuroscience 116, 213-222.
125. Neumann, H., Kotter, M. R., and Franklin, R. J. (2009). Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 132, 288-295.
126. Nilsen,J. (2008). Estradiol and neurode-generative oxidative stress. Front. Neuroendocrinol. 29, 463-475.
127. Nimmerjahn, A., Kirchhoff, F., and Helmchen, F. (2005). Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314-1318.
128. Ohtani, H.,Nomoto, M., and Douchi, T. (2001). Chronic estrogen treatment replaces striatal dopaminergic function in ovariectomized rats. Brain Res. 900, 163-168.
129. Orr, C. F., Rowe, D. B., Mizuno, Y., Mori, H., and Halliday, G. M. (2005). A possible role for humoral immunity in the pathogen-esis of Parkinson's disease. Brain 128, 2665-2674.
130. Palacios, N., Weisskopf, M., Simon, K., Gao, X., Schwarzschild, M., and Ascherio, A. (2011). Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson's disease in men and women. Parkinsonism Relat. Disord. 16, 370-375.
131. Pasqualini, C., Olivier, V., Guibert, B., Frain,O., and Leviel,V. (1995). Acute stimulatory effect of estradiol on striatal dopamine synthesis. J. Neu-rochem. 65, 1651-1657.
132. Pavon, J. M., Whitson, H. E., and Okun, M. S. (2010). Parkinson's disease in women: a call for improved clinical studies and for comparative effectiveness research. Maturitas 65, 352-358.
133. Pelletier, G. (2010). Steroidogenic enzymes in the brain: morphological aspects. Prog. Brain Res. 181, 193-207.
134. Pesaresi, M., Maschi, O., Giatti, S., Garcia-Segura, L. M., Caruso, D., and Melcangi, R. C. (2010). Sex differences in neuroactive steroid levels in the nervous system of diabetic and non-diabetic rats. Horm. Behav. 57, 46-55.
135. Popat, R. A., Van Den Eeden, S. K., Tanner, C. M., Mcguire, V., Bernstein, A. L., Bloch, D. A., Leimpeter, A., and Nelson, L. M. (2005). Effect of reproductive factors and post-menopausal hormone use on the risk of Parkinson disease. Neurology 65, 383-390.
136. Potashkin, J. A., Blume, S. R., and Run-kle, N. K. (2010). Limitations of animal models of Parkinson's disease. Parkinsons Dis. 2011, 658083.
137. Prange-Kiel, J., and Rune, G. M. (2006). Direct and indirect effects of estrogen on rat hippocampus. Neuro-science 138, 765-772.
138. Quesada, A., and Micevych, P. E. (2004). Estrogen interacts with the IGF-1 system to protect nigrostriatal dopamine and maintain motoric behavior after 6-hydroxdopamine lesions. J. Neurosci. Res. 75, 107-116.
139. Quesada, A., Romeo, H. E., and Micevych, P. (2007). Distribution and localization patterns of estrogen receptor-beta and insulin-like growth factor-1 receptors in neurons and glial cells of the female rat sub-stantia nigra: localization of ERbeta and IGF-1R in substantia nigra. J. Comp. Neurol. 503, 198-208.
140. Quinn, N. P., and Marsden, C. D. (1986). Menstrual-related fluctuations in Parkinson's disease. Mov. Disord. 1, 85-87.
141. Ragonese, P., D'amelio, M., and Savet-tieri, G. (2006). Implications for estrogens in Parkinson's disease: an epidemiological approach. Ann. N. Y. Acad. Sci. 1089, 373-382.
142. Ramirez,A. D., Liu, X., and Menniti,F. S. (2003). Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. Neuroen-docrinology 77, 223-231.
143. Rogers, J., Mastroeni, D., Leonard, B., Joyce, J., and Grover, A. (2007). Neu-roinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? Int. Rev. Neurobiol. 82, 235-246.
144. Saldanha, C. J., Duncan, K. A., and Walters, B. J. (2009). Neuroprotective actions of brain aromatase. Front. Neuroendocrinol. 30, 106-118.
145. Sandyk, R. (1989). Estrogens and the pathophysiology of Parkinson's disease. Int. J. Neurosci. 45, 119-122.
146. Santos-Galindo, M., Acaz-Fonseca, E., Bellini, M. J., and Garcia-Segura, L. M. (2011). Sex differences in the inflammatory response of primary astrocytes to lipopolysaccharide. Biol. Sex Differ. 2, 7.
147. Saunders-Pullman, R., Gordon-Elliott, J., Parides, M., Fahn, S., Saunders, H. R., and Bressman, S. (1999). The effect of estrogen replacement on early Parkinson's disease. Neurology 52, 1417-1421.
148. Schultz, K. N., Von Esenwein, S. A., Hu, M., Bennett, A. L., Kennedy, R. T., Musatov, S., Toran-Allerand, C. D., Kaplitt, M. G., Young, L. J., and Becker, J. B. (2009). Viral vector-mediated overexpression of estrogen receptor-alpha in striatum enhances the estradiol-induced motor activity in female rats and estradiol-modulated GABA release. J. Neu-rosci. 29, 1897-1903.
149. Schwarting, R. K., and Huston, J. P. (1996). The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50, 275-331.
150. Serova, L. I., Maharjan, S., Huang, A., Sun, D., Kaley, G., and Sabban, E. L. (2004). Response of tyrosine hydroxylase and GTP cyclohydro-lase I gene expression to estrogen in brain catecholaminergic regions varies with mode of administration. Brain Res. 1015, 1-8.
151. Shadrina, M. I., Slominsky, P. A., and Limborska, S. A. (2010). Molecular mechanisms of pathogenesis of Parkinson's disease. Int. Rev. Cell Mol. Biol. 281, 229-266.
152. Sharpe, R. M. (1998). The roles of oestrogen in the male. Trends Endocrinol. Metab. 9, 371-377.
153. Shughrue, P. J. (2004). Estrogen attenuates the MPTP-induced loss of dopamine neurons from the mouse SNc despite a lack of estrogen receptors (ERalpha and ERbeta). Exp. Neurol. 190, 468-477.
154. Shulman, L. M., and Bhat, V. (2006). Gender disparities in Parkinson's disease. Expert Rev. Neurother. 6, 407-416.
155. Sierra, A., Gottfried-Blackmore, A., Mil-ner, T. A., Mcewen, B. S., and Bul-loch, K. (2008). Steroid hormone receptor expression and function in microglia. Glia 56, 659-674.
156. Simola, N., Morelli, M., and Carta, A. R. (2007). The 6-hydroxydopamine model of Parkinson's disease. Neuro-tox. Res. 11, 151-167.
157. Simunovic, F., Yi, M., Wang, Y., Stephens, R., and Sonntag, K. C. (2010). Evidence for gender-specific transcriptional profiles of nigral dopamine neurons in Parkinson disease. PLoS ONE 5, e8856. doi: 10.1371/journal.pone.0008856
158. Song, D. D., and Haber, S. N. (2000). Striatal responses to partial dopaminergic lesion: evidence for compensatory sprouting. J. Neu-rosci. 20, 5102-5114.
159. Spence, R. D., Hamby, M. E., Umeda, E., Itoh, N., Du, S., Wisdom, A. J., Cao, Y., Bondar, G., Lam, J., Ao, Y., Sandoval, F., Suriany, S., Sofroniew, M. V., and Voskuhl, R. R. (2011). Neuroprotection mediated through estrogen receptor-alpha in astro-cytes. Proc. Natl. Acad. Sci. U.S.A. 108, 8867-8872.
160. Swerdlow, R. H., Parkerjr, W. D., Cur-rie, L. J., Bennettjr, J. P., Harrison, M. B., Trugman, J. M., and Wooten, G. F. (2001). Gender ratio differences between Parkinson's disease patients and their affected relatives. Parkin-sonism Relat. Disord. 7, 129-133.
161. Tamas, A., Lubics, A., Szalontay, L., Lengvari, I., and Reglodi, D. (2005). Age and gender differences in behavioral and morphological outcome after 6-hydroxydopamine-induced lesion of the substantia nigra in rats. Behav. Brain Res. 158, 221-229.
162. Tapia-Gonzalez, S., Carrero, P., Per-nia, O., Garcia-Segura, L. M., and Diz-Chaves, Y. (2008). Selective oestrogen receptor (ER) modulators reduce microglia reactivity in vivo after peripheral inflammation: potential role of microglial ERs. J. Endocrinol. 198, 219-230.
163. Taylor, K. S., Cook, J. A., and Counsell, C. E. (2007). Heterogeneity in male to female risk for Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 78, 905-906.
164. Thanky, N. R., Son, J. H., and Herbison, A. E. (2002). Sex differences in the regulation of tyrosine hydroxylase gene transcription by estrogen in the locus coeruleus of TH9-LacZ trans-genic mice. Brain Res. Mol. Brain Res. 104, 220-226.
165. Toran-Allerand, C. D. (2005). Estrogen and the brain: beyond ER-alpha, ER-beta, and 17beta-estradiol. Ann. N. Y. Acad. Sci. 1052, 136-144.
166. Tripanichkul, W., Sripanichkulchai, K., and Finkelstein, D. I. (2006). Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication. Brain Res. 1084, 28-37.
167. Tsang, K. L., Ho, S. L., and Lo, S. K. (2000). Estrogen improves motor disability in Parkinson-ian postmenopausal women with motor fluctuations. Neurology 54, 2292-2298.
168. Van Den Eeden, S. K., Tanner, C. M., Bernstein, A. L., Fross, R. D., Leim-peter, A., Bloch, D. A., and Nelson, L. M. (2003). Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 157, 1015-1022.
169. van Nas, A., Guhathakurta, D., Wang, S. S., Yehya, N., Horvath, S., Zhang, B., Ingram-Drake, L., Chaudhuri, G., Schadt, E. E., Drake, T. A., Arnold, A. P., and Lusis, A. J. (2009). Elucidating the role of gonadal hormones in sexually dimorphic gene coexpres-sion networks. Endocrinology 150, 1235-1249.
170. Vegeto, E., Belcredito, S., Etteri, S., Ghisletti, S., Brusadelli, A., Meda, C., Krust, A., Dupont, S., Ciana, P., Chambon, P., and Maggi, A. (2003). Estrogen receptor-alpha mediates the brain antiinflammatory activity of estradiol. Proc. Natl. Acad. Sci. U.S.A. 100, 9614-9619.
171. Vegeto, E., Belcredito, S., Ghisletti, S., Meda, C., Etteri, S., and Maggi, A. (2006). The endogenous estrogen status regulates microglia reactivity in animal models of neu-roinflammation. Endocrinology 147, 2263-2272.
172. Vegeto, E., Benedusi, V., and Maggi, A. (2008). Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front. Neuroendocrinol. 29, 507-519.
173. Vives-Bauza, C., Tocilescu, M., Devries, R. L., Alessi, D. M., Jackson-Lewis, V., and Przedborski, S. (2010). Control of mitochondrial integrity in Parkinson's disease. Prog. Brain Res. 183, 99-113.
174. Weintraub, D., Comella, C. L., and Horn, S. (2008). Parkinson's disease - Part 1: pathophysiology, symptoms, burden, diagnosis, and assessment. Am. J. Manag. Care 14, S40-S48.
175. Westberg, L., Hakansson, A., Melke, J., Shahabi, H. N., Nilsson, S., Buer-venich, S., Carmine, A., Ahlberg, J., Grundell, M. B., Schulhof, B., Kling-borg, K., Holmberg, B., Sydow, O., Olson, L., Johnels, E. B., Eriksson, E., and Nissbrandt, H. (2004). Association between the estrogen receptor beta gene and age of onset of Parkinson's disease. Psychoneuroen-docrinology 29, 993-998.
176. Wise, P. M., Dubal, D. B., Rau, S. W., Brown,C. M., and Suzuki,S. (2005). Are estrogens protective or risk factors in brain injury and neurode-generation? Reevaluation after the Women's health initiative. Endocr. Rev. 26, 308-312.
177. Wise, P. M., Suzuki, S., and Brown, C. M. (2009). Estradiol: a hormone with diverse and contradictory neu-roprotective actions. Dialogues Clin. Neurosci. 11, 297-303.
178. Wooten, G. F., Currie, L. J., Bovbjerg, V. E., Lee, J. K., and Patrie, J. (2004). Are men at greater risk for Parkinson's disease than women? J. Neurol. Neurosurg. Psychiatry 75, 637-639.
179. Wynne, R. D., and Saldanha, C. J. (2004). Glial aromatization decreases neural injury in the zebra finch (Tae-niopygia guttata): influence on apoptosis. J. Neuroendocrinol. 16, 676-683.
180. Yokoyama, H., Uchida, H., Kuroiwa, H., Kasahara, J., and Araki, T. (2011). Role of glial cells in neurotoxin-induced animal models of Parkinson's disease. Neurol. Sci. 32, 1-7.
181. Yu, L., Kuo, Y., Cherng, C. G., Chen, H. H., and Hsu, C. H. (2002). Ovarian hormones do not attenuate methamphetamine-induced dopaminergic neurotoxicity in mice gonadectomized at 4 weeks postpartum. Neuroendocrinology 75, 282-287.
182. Yu, L., and Liao, P. C. (2000). Sex ual differences and estrous cycle in methamphetamine-induced dopamine and serotonin depletions in the striatum of mice. J. Neural Transm. 107, 419-427.
183. Yu, Y. L., and Wagner, G. C. (1994). Influence of gonadal hormones on sexual differences in sensitivity to methamphetamine-induced neu-rotoxicity. J. Neural Transm. Park. Dis. Dement. Sect. 8, 215-221.
184. Zwain, I. H., and Yen, S. S. (1999). Neurosteroidogenesis in astrocytes, oligodendrocytes, and neurons of cerebral cortex of rat brain. Endocrinology 140, 3843-3852.